This paper discusses the experience of psychodynamically oriented therapists in private practice as they contemplate raising their fees. Raising fees stirs up competing self-interest, transference-countertransference reverberations, financial fantasies and realities, ethical concerns, and uncomfortable as well as satisfied self-reflection. These dynamics are discussed under the following categories: exercise of power; incurring guilt; inappropriate entitlement; fear of loss; modeling of self-care; rapaciousness; unconscious factors; and self-esteem. A cautionary case example is provided. Six suggestions are offered to make therapists' contemplation of raising fees less stressful. The author hopes that this article will foster more open discussions among therapists about the tensions involved in raising fees and, in the process, lead to an enhanced understanding, acceptance, and detoxification of the feelings involved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1521/pdps.2021.49.4.532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Why are we still in need for novel anti-obesity medications?
Lancet Reg Health Eur
December 2024
Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany.
From the pioneering moment in 1987 when the insulinotropic effect of glucagon-like peptide 1 (GLP-1) was first demonstrated in humans, to today's pharmaceutical gold rush for GLP-1-based treatments of obesity, the journey of GLP-1 pharmacology has been nothing short of extraordinary. The sequential conceptual developments of long-acting GLP-1 receptor (GLP-1R) mono-agonists, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonists, and GLP-1R/GIPR/glucagon receptor (GcgR) triple agonists, have led to profound body weight-lowering capacities, with benefits that extend past obesity and towards obesity-associated diseases. The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain types of bariatric surgery.
View Article and Find Full Text PDFHow are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals.
Eur J Health Econ
December 2024
Department of Health Policy, London School of Economics and Political Science, Houghton street, London, WC2A 2AE, UK.
Patient organisations are increasingly involved in HTA. Given this, it is important to understand what these organisations contribute and how their voices are accounted for in the decision-making process. This study characterises inputs from patient organisations and/or their nominated patient experts in technology appraisals for ultra-rare diseases in England and Wales and seeks to understand how these are considered in NICE final recommendations.
View Article and Find Full Text PDFFuture challenges for UK regulation of brain organoid research.
Med Law Rev
December 2024
Law School, London School of Economics and Political Science, London WC2A 2AE, United Kingdom.
One of this century's most dramatic scientific developments is the reprogramming of stem cells in order to create organoids, that is, self-organizing 3D models that mimic the structure and function of human organs. This article considers whether brain organoids in particular might raise any new questions for law, now or in the near future. If complex human brain organoids were to become capable of consciousness or sentience, the current regulation of human tissue research, which protects the interests of tissue donors, might need to be supplemented in order to protect the interests of the tissue itself.
View Article and Find Full Text PDFHope is Not a Strategy: Key Lessons from COVID-19 for Future Health Crises.
Risk Manag Healthc Policy
December 2024
Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
Introduction: The COVID-19 pandemic disrupted global economies, social structures, and public health systems. However, Denmark stood out as an exception, maintaining steady life expectancy during this period. This raises important questions about the factors that strengthened the Danish healthcare system and society against the pandemic's challenges.
View Article and Find Full Text PDFA cost-reducing reimbursement programme? Effects of value-based reimbursement on healthcare costs.
Front Public Health
December 2024
Department of Health, Medicine and Caring Sciences (HMV), Linköping University, Linköping, Sweden.
Value-based reimbursement programmes have become increasingly common in attempts to bend the cost curve of healthcare without negative effects on quality. The aim of this study was to analyse the effect of introducing a value-based reimbursement programme on the cost to third-party payer. We performed a retrospective observational study with a before and after design based on the introduction of a value-based reimbursement programme in Sweden.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!